Author:
Li Fenfen,Zhao Ying,Nie Guangjun
Publisher
Springer Science and Business Media LLC
Subject
Electrical and Electronic Engineering,General Materials Science,Condensed Matter Physics,Atomic and Molecular Physics, and Optics
Reference130 articles.
1. Ruan, Q.; Wang, H. L.; Burke, L. J.; Bridle, K. R.; Li, X. X.; Zhao, C. X.; Crawford, D. H. G.; Roberts, M. S.; Liang, X. W. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. Int. J. Cancer 2020, 147, 1519–1527.
2. Li, L. J.; Wang, H. Y.; Ong, Z. Y.; Xu, K. J.; Ee, P. L. R.; Zheng, S. S.; Hedrick, J. L.; Yang, Y. Y. Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today 2010, 5, 296–312.
3. Schon, H. T.; Bartneck, M.; Borkham-Kamphorst, E.; Nattermann, J.; Lammers, T.; Tacke, F.; Weiskirchen, R. Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis. Front. Pharmacol. 2016, 7, 33.
4. Song, Y.; Kim, S. H.; Kim, K. M.; Choi, E. K.; Kim, J.; Seo, H. R. Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. Sci. Rep. 2016, 6, 36750.
5. Chen, J.; Jin, R. N.; Zhao, J.; Liu, J. H.; Ying, H. N.; Yan, H.; Zhou, S. J.; Liang, Y. L.; Huang, D. Y.; Liang, X. et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015, 367, 1–11.